Business Description
Scinopharm Taiwan Ltd
ISIN : TW0001789006
Description
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.87 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.69 | |||||
| Interest Coverage | 55.17 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 9.28 | |||||
| Beneish M-Score | -2.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.1 | |||||
| 3-Year EBITDA Growth Rate | 2.2 | |||||
| 3-Year Book Growth Rate | -0.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.27 | |||||
| 9-Day RSI | 63.58 | |||||
| 14-Day RSI | 55.23 | |||||
| 6-1 Month Momentum % | -16.78 | |||||
| 12-1 Month Momentum % | -11.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.35 | |||||
| Quick Ratio | 6.64 | |||||
| Cash Ratio | 5.73 | |||||
| Days Inventory | 294.22 | |||||
| Days Sales Outstanding | 54.66 | |||||
| Days Payable | 24.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.26 | |||||
| Dividend Payout Ratio | 0.6 | |||||
| 3-Year Dividend Growth Rate | 10.1 | |||||
| Forward Dividend Yield % | 1.26 | |||||
| 5-Year Yield-on-Cost % | 1.11 | |||||
| Shareholder Yield % | 1.39 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.53 | |||||
| Operating Margin % | 12.78 | |||||
| Net Margin % | 11.43 | |||||
| FCF Margin % | 6.82 | |||||
| ROE % | 3.84 | |||||
| ROA % | 3.38 | |||||
| ROIC % | 5.1 | |||||
| ROC (Joel Greenblatt) % | 7.99 | |||||
| ROCE % | 4.52 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 47.9 | |||||
| Forward PE Ratio | 99.04 | |||||
| PE Ratio without NRI | 47.9 | |||||
| Shiller PE Ratio | 39.11 | |||||
| Price-to-Owner-Earnings | 95.29 | |||||
| PS Ratio | 5.62 | |||||
| PB Ratio | 1.81 | |||||
| Price-to-Tangible-Book | 1.82 | |||||
| Price-to-Free-Cash-Flow | 78.01 | |||||
| Price-to-Operating-Cash-Flow | 34.86 | |||||
| EV-to-EBIT | 31.39 | |||||
| EV-to-EBITDA | 15.95 | |||||
| EV-to-Revenue | 4.48 | |||||
| EV-to-FCF | 63.36 | |||||
| Price-to-Projected-FCF | 1.64 | |||||
| Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Graham-Number | 1.97 | |||||
| Price-to-Net-Current-Asset-Value | 3.68 | |||||
| Price-to-Net-Cash | 7.19 | |||||
| Earnings Yield (Greenblatt) % | 3.19 | |||||
| FCF Yield % | 1.25 | |||||
| Forward Rate of Return (Yacktman) % | 6.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scinopharm Taiwan Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 3,492.972 | ||
| EPS (TTM) (NT$) | 0.5 | ||
| Beta | 0.17 | ||
| Volatility % | 16.7 | ||
| 14-Day RSI | 55.23 | ||
| 14-Day ATR (NT$) | 0.389753 | ||
| 20-Day SMA (NT$) | 23.4675 | ||
| 12-1 Month Momentum % | -11.58 | ||
| 52-Week Range (NT$) | 22.95 - 30.5 | ||
| Shares Outstanding (Mil) | 790.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scinopharm Taiwan Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scinopharm Taiwan Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scinopharm Taiwan Ltd Frequently Asked Questions
What is Scinopharm Taiwan Ltd(TPE:1789)'s stock price today?
The current price of TPE:1789 is NT$23.95. The 52 week high of TPE:1789 is NT$30.50 and 52 week low is NT$22.95.
When is next earnings date of Scinopharm Taiwan Ltd(TPE:1789)?
The next earnings date of Scinopharm Taiwan Ltd(TPE:1789) is .
Does Scinopharm Taiwan Ltd(TPE:1789) pay dividends? If so, how much?
The Dividend Yield %  of Scinopharm Taiwan Ltd(TPE:1789) is 1.26% (As of Today), Highest Dividend Payout Ratio of Scinopharm Taiwan Ltd(TPE:1789) was 1.82. The lowest was 0.22. And the median was 0.93. The  Forward Dividend Yield % of Scinopharm Taiwan Ltd(TPE:1789) is 1.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers